TABLE 1.
Clinical and disease characteristics of breast cancer patients.
| Early breast cancer | Metastatic breast cancer | |||
|---|---|---|---|---|
| – | Whole group | Triple negative | – | |
| Characteristic | n (%) | n (%) | Characteristic | n (%) |
| Number of patients | 140 | 31 (22.1) | Number of patients | 64 |
| Age (years) | Age (years) | |||
| Median (range) | 55 (27–82) | 56 (38–75) | Median (range) | 60 (30–82) |
| Menopausal status | Menopausal status | |||
| Pre | 53 (37.9) | 12 (38.7) | Pre | 27 (42) |
| Post | 87 (62.1) | 19 (61.3) | Post | 37 (58) |
| Tumor size (cm) | Performance status | |||
| T1 | 62 (44.3) | 10 (32.3) | 0–1 | 50 (78) |
| T2 | 70 (50) | 19 (61.3) | 2 | 14(22) |
| T3 | 8 (5.7) | 2 (6.5) | – | – |
| Histological grade | Histological Grade | |||
| I | 5 (3.6) | – | I/II | 27 (42) |
| II | 56 (40) | – | III | 33 (52) |
| III | 67 (47.9) | 7 (22.6) | Unknown | 4 (6) |
| Lobular | 8 (5.7) | 23 (74.3) | – | – |
| Unknown | 4 (2.9) | 1 (3.2) | – | – |
| Infiltrated lymph nodes | Stage at diagnosis | |||
| 0 | 60 (42.9) | 21 (80.6) | Recurrent | 19 (30) |
| 1–3 | 50 (35.7) | 4 (12.9) | de novo metastatic | 45 (70) |
| ≥4 | 30 (21.4) | 6 (19.4) | – | – |
| ER status | ER status | |||
| Positive | 88 (62.9) | – | Positive | 50 (78) |
| Negative | 52 (37.1) | – | Negative | 14 (22) |
| PR status | PR status | |||
| Positive | 88 (62.9) | – | Positive | 45 (70) |
| Negative | 52 (37.1) | – | Negative | 19 (30) |
| Her2 status | Her2 status | |||
| Positive | 19 (13.6) | – | Positive | 16 (25) |
| Negative | 121 (86.4) | – | Negative | 48 (75) |
| Adjuvant chemotherapy | First line chemotherapy | |||
| Anthracyclines-based | 10 (7.1) | 2 (6.4) | Taxane-based | 40 (63) |
| Taxanes + Antracyclines | 95 (67.9) | 27 (87.0) | Taxanes + Anthracyclines | 2 (3) |
| Taxanes-based | 26 (18.6) | 2 (6.5) | Anthracycline-based | 15 (23) |
| Others | 3 (2.1) | – | Others | 7 (11) |
| No | 6 (4.3) | – | – | |
| Relapse status | Relapse status | |||
| Non-relapse | 94 (67.1) | 19 (61.3) | Non-relapse | 1 (1.6) |
| Relapse | 46 (32.9) | 12 (38.7) | Relapse | 63 (98.4) |
| Survival status | Survival status | |||
| Alive | 111 (79.3) | 22 (71.0) | Alive | 9 (14.1) |
| Dead | 29 (20.7) | 9 (29.0) | Dead | 55 (85.9) |
| – | Response to treatment | |||
| – | PR | 39 (61) | ||
| – | SD | 10 (16) | ||
| – | PD | 15 (23) | ||
| – | Visceral metastasis | |||
| – | Yes | 55 (86) | ||
| – | No | 9 (14) | ||
| – | Non visceral metastasis | |||
| – | Yes | 53 (83) | ||
| – | No | 11 (17) | ||
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor two; PR, partial response; SD, stable disease, PD, progressive disease.